Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Metseras portfolio includes: injectable GLP-1 receptor agonist MET-097i (phase 2), amylin analog candidate MET-233i (phase I), two oral GLP-1 RA candidates expected to begin clinical trials imminently, and additional preclinical nutrient-stimulated hormone therapeutics
Gamma-glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system
A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology
Individuals with a history of restrictive eating, body dysmorphia, or disordered eating should use GLP-1 medications alongside mental health treatment
US$ 20.75
US$ 26.77
US$ 22.35
US$ 20.70
US$ 25.76
